WP-1303 is under clinical development by Worg Pharmaceuticals Hangzhou and currently in Phase II for Multiple Sclerosis. According to GlobalData, Phase II drugs for Multiple Sclerosis have a 49% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how WP-1303’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

WP-1303 overview

WP-1303 is under development for the treatment of intermediate, multiple sclerosis and posterior uveitis. The drug candidate is developed based on the apitope discovery platform.

Worg Pharmaceuticals Hangzhou overview

Worg Pharmaceuticals is a clinical-stage biopharmaceutical company developing new treatments for allergy and other diseases with high unmet medical needs and considerable commercial potential. It is headquartered in Hangzhou, Zhejiang, China.

For a complete picture of WP-1303’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.